| P50 | author | Ian Bruce | Q30348366 |
| | Dafna D. Gladman | Q37605821 |
| P2093 | author name string | Urowitz M | |
| P2860 | cites work | Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus | Q28319260 |
| | Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality | Q33488402 |
| | Peripheral vascular disease in patients with systemic lupus erythematosus | Q33564222 |
| | Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. | Q35171679 |
| | Experimental induction of athero-arteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet. I. Effect of repeated injections of horse serum in rabbits fed a dietary cholesterol supplement | Q36268330 |
| | Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 |
| | Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. | Q40415334 |
| | An update on coronary risk factors | Q40482679 |
| | Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice | Q40937418 |
| | Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease | Q41288539 |
| | Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 |
| | Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2. | Q41874207 |
| | The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. | Q41924668 |
| | The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. | Q41937905 |
| | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 |
| | The bimodal mortality pattern of systemic lupus erythematosus | Q43703475 |
| | Lipid profiles in patients with systemic lupus erythematosus | Q43893016 |
| | Mortality in systemic lupus erythematosus: the bimodal pattern revisited | Q43971969 |
| | Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices | Q44589658 |
| | The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta | Q45129182 |
| | Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. | Q51577475 |
| | Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. | Q51578946 |
| | Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. | Q51584611 |
| | Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. | Q52905161 |
| | Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus | Q60680877 |
| | Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 |
| | Morbidity in systemic lupus erythematosus | Q69148719 |
| | Ischemic heart disease in systemic lupus erythematosus. A retrospective study of 65 patients treated with prednisolone | Q69387458 |
| | Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids | Q69414146 |
| | Hyperhomocysteinemia: an independent risk factor for vascular disease | Q70131136 |
| | Dyslipoproteinemia in pediatric systemic lupus erythematosus | Q70396550 |
| | Vitamin status and intake as primary determinants of homocysteinemia in an elderly population | Q72305071 |
| | Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity | Q72418673 |
| | Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study | Q72573690 |
| | Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus | Q72607855 |
| | Natural history of hypercholesterolemia in systemic lupus erythematosus | Q73101137 |
| | Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 |
| | Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus | Q73167867 |
| | Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years | Q73442108 |
| | Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study | Q77099358 |
| | Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus | Q77909409 |
| P433 | issue | 1 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| | atherosclerosis | Q12252367 |
| P304 | page(s) | 19-23 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Atherosclerosis and systemic lupus erythematosus. | |
| P478 | volume | 2 | |